AIM ImmunoTech Inc (AIM)

[makinezmoney]

$AIM: Nicely Done........ I like this AM news too


Definitely a positive step in that provisional TradeMark.


Count me in on this at $1.32 this AM


It should see $2 easy on this.



And make up for that loss on MYO you had the other day



GO $AIM


****************************************************************


Press Release: AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus
6:30 AM ET 2/11/20 | Dow Jones
Related Quotes


8:00 PM ET 2/11/20
Symbol Last % Chg
AIM
1.06 0.00%
Real time quote.



Ampligen(R) obtained 100% survival rate at clinically achievable human

dosage levels for SARS in animal experiments

Ampligen key to proposed broad-spectrum 'universal' coronavirus vaccine

OCALA, Fla., Feb. 11, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE

American: AIM) today announced the filing of three provisional patent

applications related to its drug candidate Ampligen in the company's

efforts toward joining the global health community in the fight against

the deadly Wuhan coronavirus that has so far infected approximately

40,000 people and killed almost one thousand, primarily in China.

Coronaviruses are a large family of viruses, including the deadly Severe

Acute Respiratory Syndrome (SARS). After a 2002 SARS outbreak in the

Guangdong province of southern China caused more than 8,000 cases and

more than 800 deaths, the United States' National Institutes of Health

contracted studies to evaluate potential treatments for SARS. Ampligen

achieved a 100% survival rate -- as compared to 100% mortality -- at

clinically achievable human dosage levels in animal experiments. The

SARS virus is very similar in key RNA sequences to the Wuhan coronavirus,

and the company expects Ampligen to be similarly effective with the

Wuhan coronavirus.

AIM -- which is an immuno-pharma company focused on the research and

development of therapeutics to treat immune disorders, viral diseases

and multiple types of cancers -- is already focused on avenues to

provide the company's Ampligen technology to the countries primarily

afflicted by the pandemic.

AIM believes that Ampligen has the potential to be both an early-onset

treatment for and prophylaxis against the Wuhan coronavirus, which

originated in China before quickly spreading to other countries. The

company's three provisional patent applications include: 1) Ampligen as

a therapy for the Wuhan coronavirus; 2) Ampligen as part of a proposed

intranasal universal coronavirus vaccine that combines Ampligen with

inactivated Wuhan coronavirus, conveying immunity and cross-protection

and; 3) a high-volume manufacturing process for Ampligen. Under the

Patent Cooperation Treaty of 1970, which provides international

protections for patents, the three provisional patent applications can

convert to international patent applications based on the date of their

filings. Alternatively, direct national filings in many countries are

possible under the Paris Convention for the Protection of Industrial

Property of 1883 -- an international agreement. China, the epicenter of

the epidemic, is a signatory of both the treaty and the agreement.

"Our analysis of the RNA sequences of the SARS virus and the Wuhan

coronavirus and our research lead AIM to believe Ampligen has

significant therapeutic potential as both an early-onset treatment and

prophylaxis against this new and deadly virus," said AIM CEO Thomas K.

Equels. "If clinical trials follow the results of SARS animal testing,

this means helping people who are already sick as well as a prophylaxis

for people directly exposed to the virus as it spreads, which is

especially important for the medical professionals in hospital-like

settings working to contain the global emergency, and those people

quarantined in camps and on cruise ships. AIM's universal coronavirus

vaccine concept is primarily meant to inoculate against the Wuhan

coronavirus, but, through Ampligen's unique capabilities, could also

protect against other forms of coronavirus and future mutations of the

Wuhan coronavirus. AIM is a small immunological research company, but we

want to do our part. We believe humanity must stand together to defeat

such viral threats. This is our effort to make a difference in this

worldwide threat posed by the Wuhan coronavirus."

Ampligen is the only known specific Toll-Like Receptor 3 agonist based

on synthetic double-stranded RNA with a well-developed intravenous,

intraperitoneal and intranasal safety profile while demonstrating strong

antiviral activity against a broad spectrum of viruses. The drug is also

being used in multiple ongoing immuno-oncology clinical studies. AIM has

recently produced more than 10,000 vials of Ampligen.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research

and development of therapeutics to treat immune disorders, viral

diseases and multiple types of cancers. AIM's flagship products include

the Argentina-approved drug rintatolimod (trade names Ampligen(R) or

Rintamod(R) ) and the FDA-approved drug Alferon N Injection(R) . Based

on results of published, peer-reviewed pre-clinical studies and clinical

trials, AIM believes that Ampligen(R) may have broad-spectrum anti-viral

and anti-cancer properties. Clinical trials of Ampligen(R) include

studies of cancer patients with renal cell carcinoma, malignant melanoma,

colorectal cancer, advanced recurrent ovarian cancer and triple negative

metastatic breast cancer. These and other potential uses will require

additional clinical trials to confirm the safety and effectiveness data

necessary to support regulatory approval and additional funding.

Rintatolimod is a double-stranded RNA being developed for globally

important debilitating diseases and disorders of the immune system.

Cautionary Statement

Some of the statements included in this press release may be

forward-looking statements that involve a number of risks and

uncertainties. For example, the filing of provisional patent

applications provides no assurance that patents will ultimately be

granted. No assurance can be made as to any future clinical trials

related to the matter herein. No assurance can be given as to whether

the current or planned trials will be successful or yield favorable data

and the trials are subject to many factors including lack of regulatory

approval(s), lack of study drug, or a change in priorities at the

institutions sponsoring other trials. In addition, initiation of planned

clinical trials may not occur secondary to many factors including lack

of regulatory approval(s) or lack of study drug. Even if these clinical

trials are initiated, we cannot assure that the clinical studies will be

successful or yield any useful data or require additional funding. Among

other things, for forward-looking statements, we claim the protection of

the safe harbor for forward-looking statements contained in the Private

Securities Litigation Reform Act of 1995. Any forward-looking statements

set forth in this press release speak only as of the date of this press

release. We do not undertake to update any of these forward-looking

statements to reflect events or circumstances that occur after the date

hereof. This press release and prior releases are available at

www.aimimmuno.com. The information found on our website is not

incorporated by reference into this press release and is included for

reference purposes only.

Contacts:

Crescendo Communications, LLC

Phone: [phone]

Email:

https://www.globenewswire.com/Tracker?data=Tp9mWy9cd-m9T0c218xDP0hiA9tB9FHT5OZjhHYKwy9jwLJYiwVojT2jTg7KeNBSq9BnnnxQIOM89SnL3hFfcK9d283UKTT2NrFLaTFozzk=

[e-mail]

AIM ImmunoTech Inc.

Phone: [phone]

Email:

https://www.globenewswire.com/Tracker?data=nBBsoDQ9bbvt5wddaVT2IvDn0nIj9-vCI76FRWrqeqVmTxDExd4Q2smKWjb61_FtoSRv55bNEzHrSmjUcVbpvQ==

[e-mail]

A photo accompanying this announcement is available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/d12855ed-8007-4ebe-bef5-6b3aaac80729.





> Dow Jones Newswires

February 11, 2020 06:30 ET (11:30 GMT)